Association of PD‐L1 expression with driver gene mutations and clinicopathological characteristics in non‐small cell lung cancer: A real‐world study of 10 441 patients
- Autores
- Ruiz, Gonzalo; Enrico, Diego Hernán; Mahmoud, Yamil Damián; Ruiz, Alan; Cantarella, María Florencia; Leguina, Laura; Barberis, Mariana; Beña, Asunción; Brest, Esteban; Starapoli, Solange; Mendoza Bertelli, Andrea; Tsou, Florencia; Pupareli, Carmen; Coppola, María Pía; Scocimarro, Alejandra; Sena, Susana; Levit, Patricio; Perfetti, Aldo; Aman, Enrique; Girotti, María Romina; Arrieta, Oscar; Martín, Claudio; Salanova, Rubén
- Año de publicación
- 2024
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Background: Programmed death ligand-1 (PD-L1) expression is a well-known predictive biomarker of response to immune checkpoint blockade in non-small cell lung cancer (NSCLC). However, there is limited evidence of the relationship between PDL1 expression, clinicopathological features, and their association with major driver mutations in NSCLC patients in Latin America. Methods: This retrospective study included patients from Argentina with advanced NSCLC, and centralized evaluation of PD-L1 expression concurrently with genomic alterations in the driver genes EGFR, ALK, ROS1, BRAF, and/or KRAS G12C in FFPE tissue samples. Results: A total of 10 441 patients with advanced NSCLC were analyzed. Adenocarcinoma was the most frequent histological subtype (71.1%). PD-L1 expression was categorized as PD-L1 negative (45.1%), PD-L1 positive low-expression 1%–49% (32.3%), and PD-L1 positive high-expression ≥50% (22.6%). Notably, current smokers and males were more likely to have tumors with PD-L1 tumor proportion score (TPS) ≥50% and ≥ 80% expression, respectively (p < 0.001 and p = 0.013). Tumors with non-adenocarcinoma histology had a significantly higher median PD-L1 expression (p < 0.001). Additionally, PD-L1 in distant nodes was more likely ≥50% (OR 1.60 [95% CI: 1.14–2.25, p < 0.01]). In the multivariate analysis, EGFR-positive tumors were more commonly associated with PD-L1 low expression (OR 0.62 [95% CI: 0.51– 0.75], p < 0.01), while ALK-positive tumors had a significant risk of being PD-L1 positive (OR 1.81 [95% CI: 1.30–2.52], p < 0.01). Conclusions: PD-L1 expression was associated with well-defined clinicopathological and genomic features. These findings provide a comprehensive view of the expression of PD-L1 in patients with advanced NSCLC in a large Latin American cohort.
Fil: Ruiz, Gonzalo. BIOMAKERS; Argentina
Fil: Enrico, Diego Hernán. Instituto Alexander Fleming.; Argentina
Fil: Mahmoud, Yamil Damián. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina. Universidad Argentina de la Empresa; Argentina
Fil: Ruiz, Alan. BIOMAKERS; Argentina
Fil: Cantarella, María Florencia. BIOMAKERS; Argentina
Fil: Leguina, Laura. BIOMAKERS; Argentina
Fil: Barberis, Mariana. BIOMAKERS; Argentina
Fil: Beña, Asunción. BIOMAKERS; Argentina
Fil: Brest, Esteban. BIOMAKERS; Argentina
Fil: Starapoli, Solange. BIOMAKERS; Argentina
Fil: Mendoza Bertelli, Andrea. BIOMAKERS; Argentina
Fil: Tsou, Florencia. Instituto Alexander Fleming.; Argentina
Fil: Pupareli, Carmen. Instituto Alexander Fleming.; Argentina
Fil: Coppola, María Pía. Provincia de Buenos Aires. Ministerio de Salud. Hospital "Dr. Antonio A. Cetrángolo"; Argentina
Fil: Scocimarro, Alejandra. Provincia de Buenos Aires. Ministerio de Salud. Hospital "Dr. Antonio A. Cetrángolo"; Argentina
Fil: Sena, Susana. Hospital Aleman; Argentina
Fil: Levit, Patricio. Union Personal. Accord Salud; Argentina
Fil: Perfetti, Aldo. Centro de Educaciones Médicas e Investigación Clínica "Norberto Quirno"; Argentina. Union Personal. Accord Salud; Argentina
Fil: Aman, Enrique. Swiss Medical Group; Argentina
Fil: Girotti, María Romina. Universidad Argentina de la Empresa; Argentina. BIOMAKERS; Argentina
Fil: Arrieta, Oscar. Instituto Nacional de Cancerologia; México
Fil: Martín, Claudio. Instituto Alexander Fleming.; Argentina
Fil: Salanova, Rubén. BIOMAKERS; Argentina - Materia
-
PROGRAMMED DEATH-LIGAND 1
NON-SMALL CELL LUNG CANCER
IMMUNOHISTOCHEMESTRY
DRIVER MUTATIONS
GENOMIC ALTERATIONS
NSCLC - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
.jpg)
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/268197
Ver los metadatos del registro completo
| id |
CONICETDig_eaaffdd44f0f8d2a6465308c50a760b2 |
|---|---|
| oai_identifier_str |
oai:ri.conicet.gov.ar:11336/268197 |
| network_acronym_str |
CONICETDig |
| repository_id_str |
3498 |
| network_name_str |
CONICET Digital (CONICET) |
| spelling |
Association of PD‐L1 expression with driver gene mutations and clinicopathological characteristics in non‐small cell lung cancer: A real‐world study of 10 441 patientsRuiz, GonzaloEnrico, Diego HernánMahmoud, Yamil DamiánRuiz, AlanCantarella, María FlorenciaLeguina, LauraBarberis, MarianaBeña, AsunciónBrest, EstebanStarapoli, SolangeMendoza Bertelli, AndreaTsou, FlorenciaPupareli, CarmenCoppola, María PíaScocimarro, AlejandraSena, SusanaLevit, PatricioPerfetti, AldoAman, EnriqueGirotti, María RominaArrieta, OscarMartín, ClaudioSalanova, RubénPROGRAMMED DEATH-LIGAND 1NON-SMALL CELL LUNG CANCERIMMUNOHISTOCHEMESTRYDRIVER MUTATIONSGENOMIC ALTERATIONSNSCLChttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Background: Programmed death ligand-1 (PD-L1) expression is a well-known predictive biomarker of response to immune checkpoint blockade in non-small cell lung cancer (NSCLC). However, there is limited evidence of the relationship between PDL1 expression, clinicopathological features, and their association with major driver mutations in NSCLC patients in Latin America. Methods: This retrospective study included patients from Argentina with advanced NSCLC, and centralized evaluation of PD-L1 expression concurrently with genomic alterations in the driver genes EGFR, ALK, ROS1, BRAF, and/or KRAS G12C in FFPE tissue samples. Results: A total of 10 441 patients with advanced NSCLC were analyzed. Adenocarcinoma was the most frequent histological subtype (71.1%). PD-L1 expression was categorized as PD-L1 negative (45.1%), PD-L1 positive low-expression 1%–49% (32.3%), and PD-L1 positive high-expression ≥50% (22.6%). Notably, current smokers and males were more likely to have tumors with PD-L1 tumor proportion score (TPS) ≥50% and ≥ 80% expression, respectively (p < 0.001 and p = 0.013). Tumors with non-adenocarcinoma histology had a significantly higher median PD-L1 expression (p < 0.001). Additionally, PD-L1 in distant nodes was more likely ≥50% (OR 1.60 [95% CI: 1.14–2.25, p < 0.01]). In the multivariate analysis, EGFR-positive tumors were more commonly associated with PD-L1 low expression (OR 0.62 [95% CI: 0.51– 0.75], p < 0.01), while ALK-positive tumors had a significant risk of being PD-L1 positive (OR 1.81 [95% CI: 1.30–2.52], p < 0.01). Conclusions: PD-L1 expression was associated with well-defined clinicopathological and genomic features. These findings provide a comprehensive view of the expression of PD-L1 in patients with advanced NSCLC in a large Latin American cohort.Fil: Ruiz, Gonzalo. BIOMAKERS; ArgentinaFil: Enrico, Diego Hernán. Instituto Alexander Fleming.; ArgentinaFil: Mahmoud, Yamil Damián. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina. Universidad Argentina de la Empresa; ArgentinaFil: Ruiz, Alan. BIOMAKERS; ArgentinaFil: Cantarella, María Florencia. BIOMAKERS; ArgentinaFil: Leguina, Laura. BIOMAKERS; ArgentinaFil: Barberis, Mariana. BIOMAKERS; ArgentinaFil: Beña, Asunción. BIOMAKERS; ArgentinaFil: Brest, Esteban. BIOMAKERS; ArgentinaFil: Starapoli, Solange. BIOMAKERS; ArgentinaFil: Mendoza Bertelli, Andrea. BIOMAKERS; ArgentinaFil: Tsou, Florencia. Instituto Alexander Fleming.; ArgentinaFil: Pupareli, Carmen. Instituto Alexander Fleming.; ArgentinaFil: Coppola, María Pía. Provincia de Buenos Aires. Ministerio de Salud. Hospital "Dr. Antonio A. Cetrángolo"; ArgentinaFil: Scocimarro, Alejandra. Provincia de Buenos Aires. Ministerio de Salud. Hospital "Dr. Antonio A. Cetrángolo"; ArgentinaFil: Sena, Susana. Hospital Aleman; ArgentinaFil: Levit, Patricio. Union Personal. Accord Salud; ArgentinaFil: Perfetti, Aldo. Centro de Educaciones Médicas e Investigación Clínica "Norberto Quirno"; Argentina. Union Personal. Accord Salud; ArgentinaFil: Aman, Enrique. Swiss Medical Group; ArgentinaFil: Girotti, María Romina. Universidad Argentina de la Empresa; Argentina. BIOMAKERS; ArgentinaFil: Arrieta, Oscar. Instituto Nacional de Cancerologia; MéxicoFil: Martín, Claudio. Instituto Alexander Fleming.; ArgentinaFil: Salanova, Rubén. BIOMAKERS; ArgentinaWiley2024-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/268197Ruiz, Gonzalo; Enrico, Diego Hernán; Mahmoud, Yamil Damián; Ruiz, Alan; Cantarella, María Florencia; et al.; Association of PD‐L1 expression with driver gene mutations and clinicopathological characteristics in non‐small cell lung cancer: A real‐world study of 10 441 patients; Wiley; Thoracic Cancer; 15; 11; 3-2024; 895-9051759-77061759-7714CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/10.1111/1759-7714.15244info:eu-repo/semantics/altIdentifier/doi/10.1111/1759-7714.15244info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:56:27Zoai:ri.conicet.gov.ar:11336/268197instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:56:27.423CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
| dc.title.none.fl_str_mv |
Association of PD‐L1 expression with driver gene mutations and clinicopathological characteristics in non‐small cell lung cancer: A real‐world study of 10 441 patients |
| title |
Association of PD‐L1 expression with driver gene mutations and clinicopathological characteristics in non‐small cell lung cancer: A real‐world study of 10 441 patients |
| spellingShingle |
Association of PD‐L1 expression with driver gene mutations and clinicopathological characteristics in non‐small cell lung cancer: A real‐world study of 10 441 patients Ruiz, Gonzalo PROGRAMMED DEATH-LIGAND 1 NON-SMALL CELL LUNG CANCER IMMUNOHISTOCHEMESTRY DRIVER MUTATIONS GENOMIC ALTERATIONS NSCLC |
| title_short |
Association of PD‐L1 expression with driver gene mutations and clinicopathological characteristics in non‐small cell lung cancer: A real‐world study of 10 441 patients |
| title_full |
Association of PD‐L1 expression with driver gene mutations and clinicopathological characteristics in non‐small cell lung cancer: A real‐world study of 10 441 patients |
| title_fullStr |
Association of PD‐L1 expression with driver gene mutations and clinicopathological characteristics in non‐small cell lung cancer: A real‐world study of 10 441 patients |
| title_full_unstemmed |
Association of PD‐L1 expression with driver gene mutations and clinicopathological characteristics in non‐small cell lung cancer: A real‐world study of 10 441 patients |
| title_sort |
Association of PD‐L1 expression with driver gene mutations and clinicopathological characteristics in non‐small cell lung cancer: A real‐world study of 10 441 patients |
| dc.creator.none.fl_str_mv |
Ruiz, Gonzalo Enrico, Diego Hernán Mahmoud, Yamil Damián Ruiz, Alan Cantarella, María Florencia Leguina, Laura Barberis, Mariana Beña, Asunción Brest, Esteban Starapoli, Solange Mendoza Bertelli, Andrea Tsou, Florencia Pupareli, Carmen Coppola, María Pía Scocimarro, Alejandra Sena, Susana Levit, Patricio Perfetti, Aldo Aman, Enrique Girotti, María Romina Arrieta, Oscar Martín, Claudio Salanova, Rubén |
| author |
Ruiz, Gonzalo |
| author_facet |
Ruiz, Gonzalo Enrico, Diego Hernán Mahmoud, Yamil Damián Ruiz, Alan Cantarella, María Florencia Leguina, Laura Barberis, Mariana Beña, Asunción Brest, Esteban Starapoli, Solange Mendoza Bertelli, Andrea Tsou, Florencia Pupareli, Carmen Coppola, María Pía Scocimarro, Alejandra Sena, Susana Levit, Patricio Perfetti, Aldo Aman, Enrique Girotti, María Romina Arrieta, Oscar Martín, Claudio Salanova, Rubén |
| author_role |
author |
| author2 |
Enrico, Diego Hernán Mahmoud, Yamil Damián Ruiz, Alan Cantarella, María Florencia Leguina, Laura Barberis, Mariana Beña, Asunción Brest, Esteban Starapoli, Solange Mendoza Bertelli, Andrea Tsou, Florencia Pupareli, Carmen Coppola, María Pía Scocimarro, Alejandra Sena, Susana Levit, Patricio Perfetti, Aldo Aman, Enrique Girotti, María Romina Arrieta, Oscar Martín, Claudio Salanova, Rubén |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
PROGRAMMED DEATH-LIGAND 1 NON-SMALL CELL LUNG CANCER IMMUNOHISTOCHEMESTRY DRIVER MUTATIONS GENOMIC ALTERATIONS NSCLC |
| topic |
PROGRAMMED DEATH-LIGAND 1 NON-SMALL CELL LUNG CANCER IMMUNOHISTOCHEMESTRY DRIVER MUTATIONS GENOMIC ALTERATIONS NSCLC |
| purl_subject.fl_str_mv |
https://purl.org/becyt/ford/1.6 https://purl.org/becyt/ford/1 |
| dc.description.none.fl_txt_mv |
Background: Programmed death ligand-1 (PD-L1) expression is a well-known predictive biomarker of response to immune checkpoint blockade in non-small cell lung cancer (NSCLC). However, there is limited evidence of the relationship between PDL1 expression, clinicopathological features, and their association with major driver mutations in NSCLC patients in Latin America. Methods: This retrospective study included patients from Argentina with advanced NSCLC, and centralized evaluation of PD-L1 expression concurrently with genomic alterations in the driver genes EGFR, ALK, ROS1, BRAF, and/or KRAS G12C in FFPE tissue samples. Results: A total of 10 441 patients with advanced NSCLC were analyzed. Adenocarcinoma was the most frequent histological subtype (71.1%). PD-L1 expression was categorized as PD-L1 negative (45.1%), PD-L1 positive low-expression 1%–49% (32.3%), and PD-L1 positive high-expression ≥50% (22.6%). Notably, current smokers and males were more likely to have tumors with PD-L1 tumor proportion score (TPS) ≥50% and ≥ 80% expression, respectively (p < 0.001 and p = 0.013). Tumors with non-adenocarcinoma histology had a significantly higher median PD-L1 expression (p < 0.001). Additionally, PD-L1 in distant nodes was more likely ≥50% (OR 1.60 [95% CI: 1.14–2.25, p < 0.01]). In the multivariate analysis, EGFR-positive tumors were more commonly associated with PD-L1 low expression (OR 0.62 [95% CI: 0.51– 0.75], p < 0.01), while ALK-positive tumors had a significant risk of being PD-L1 positive (OR 1.81 [95% CI: 1.30–2.52], p < 0.01). Conclusions: PD-L1 expression was associated with well-defined clinicopathological and genomic features. These findings provide a comprehensive view of the expression of PD-L1 in patients with advanced NSCLC in a large Latin American cohort. Fil: Ruiz, Gonzalo. BIOMAKERS; Argentina Fil: Enrico, Diego Hernán. Instituto Alexander Fleming.; Argentina Fil: Mahmoud, Yamil Damián. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina. Universidad Argentina de la Empresa; Argentina Fil: Ruiz, Alan. BIOMAKERS; Argentina Fil: Cantarella, María Florencia. BIOMAKERS; Argentina Fil: Leguina, Laura. BIOMAKERS; Argentina Fil: Barberis, Mariana. BIOMAKERS; Argentina Fil: Beña, Asunción. BIOMAKERS; Argentina Fil: Brest, Esteban. BIOMAKERS; Argentina Fil: Starapoli, Solange. BIOMAKERS; Argentina Fil: Mendoza Bertelli, Andrea. BIOMAKERS; Argentina Fil: Tsou, Florencia. Instituto Alexander Fleming.; Argentina Fil: Pupareli, Carmen. Instituto Alexander Fleming.; Argentina Fil: Coppola, María Pía. Provincia de Buenos Aires. Ministerio de Salud. Hospital "Dr. Antonio A. Cetrángolo"; Argentina Fil: Scocimarro, Alejandra. Provincia de Buenos Aires. Ministerio de Salud. Hospital "Dr. Antonio A. Cetrángolo"; Argentina Fil: Sena, Susana. Hospital Aleman; Argentina Fil: Levit, Patricio. Union Personal. Accord Salud; Argentina Fil: Perfetti, Aldo. Centro de Educaciones Médicas e Investigación Clínica "Norberto Quirno"; Argentina. Union Personal. Accord Salud; Argentina Fil: Aman, Enrique. Swiss Medical Group; Argentina Fil: Girotti, María Romina. Universidad Argentina de la Empresa; Argentina. BIOMAKERS; Argentina Fil: Arrieta, Oscar. Instituto Nacional de Cancerologia; México Fil: Martín, Claudio. Instituto Alexander Fleming.; Argentina Fil: Salanova, Rubén. BIOMAKERS; Argentina |
| description |
Background: Programmed death ligand-1 (PD-L1) expression is a well-known predictive biomarker of response to immune checkpoint blockade in non-small cell lung cancer (NSCLC). However, there is limited evidence of the relationship between PDL1 expression, clinicopathological features, and their association with major driver mutations in NSCLC patients in Latin America. Methods: This retrospective study included patients from Argentina with advanced NSCLC, and centralized evaluation of PD-L1 expression concurrently with genomic alterations in the driver genes EGFR, ALK, ROS1, BRAF, and/or KRAS G12C in FFPE tissue samples. Results: A total of 10 441 patients with advanced NSCLC were analyzed. Adenocarcinoma was the most frequent histological subtype (71.1%). PD-L1 expression was categorized as PD-L1 negative (45.1%), PD-L1 positive low-expression 1%–49% (32.3%), and PD-L1 positive high-expression ≥50% (22.6%). Notably, current smokers and males were more likely to have tumors with PD-L1 tumor proportion score (TPS) ≥50% and ≥ 80% expression, respectively (p < 0.001 and p = 0.013). Tumors with non-adenocarcinoma histology had a significantly higher median PD-L1 expression (p < 0.001). Additionally, PD-L1 in distant nodes was more likely ≥50% (OR 1.60 [95% CI: 1.14–2.25, p < 0.01]). In the multivariate analysis, EGFR-positive tumors were more commonly associated with PD-L1 low expression (OR 0.62 [95% CI: 0.51– 0.75], p < 0.01), while ALK-positive tumors had a significant risk of being PD-L1 positive (OR 1.81 [95% CI: 1.30–2.52], p < 0.01). Conclusions: PD-L1 expression was associated with well-defined clinicopathological and genomic features. These findings provide a comprehensive view of the expression of PD-L1 in patients with advanced NSCLC in a large Latin American cohort. |
| publishDate |
2024 |
| dc.date.none.fl_str_mv |
2024-03 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/268197 Ruiz, Gonzalo; Enrico, Diego Hernán; Mahmoud, Yamil Damián; Ruiz, Alan; Cantarella, María Florencia; et al.; Association of PD‐L1 expression with driver gene mutations and clinicopathological characteristics in non‐small cell lung cancer: A real‐world study of 10 441 patients; Wiley; Thoracic Cancer; 15; 11; 3-2024; 895-905 1759-7706 1759-7714 CONICET Digital CONICET |
| url |
http://hdl.handle.net/11336/268197 |
| identifier_str_mv |
Ruiz, Gonzalo; Enrico, Diego Hernán; Mahmoud, Yamil Damián; Ruiz, Alan; Cantarella, María Florencia; et al.; Association of PD‐L1 expression with driver gene mutations and clinicopathological characteristics in non‐small cell lung cancer: A real‐world study of 10 441 patients; Wiley; Thoracic Cancer; 15; 11; 3-2024; 895-905 1759-7706 1759-7714 CONICET Digital CONICET |
| dc.language.none.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/10.1111/1759-7714.15244 info:eu-repo/semantics/altIdentifier/doi/10.1111/1759-7714.15244 |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
| dc.format.none.fl_str_mv |
application/pdf application/pdf |
| dc.publisher.none.fl_str_mv |
Wiley |
| publisher.none.fl_str_mv |
Wiley |
| dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
| reponame_str |
CONICET Digital (CONICET) |
| collection |
CONICET Digital (CONICET) |
| instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
| _version_ |
1844613695311708160 |
| score |
13.070432 |